Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc.,  (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences:
  • Citi 15th Annual BioPharma Virtual Conference, Wednesday, September 9 at 1:30 pm ET
  • 2020 Cantor Global Virtual Healthcare Conference, Wednesday, September 16 at 4:40pm ET
  • Morgan Stanley Virtual 18th Annual Global Healthcare Conference, Friday, September 18 at 10:15 am ET

A live audio webcast of each presentation will be available by visiting the “Investors” section of the Arcus website at A replay of each webcast will be available for at least two weeks following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 1b/2 studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. AB154, an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab and AB154 plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit

Source: Arcus Biosciences


Katherine Bock
(510) 694-6231


Source: Arcus Biosciences, Inc.

Back to news